New therapeutic targets and agents for osteoporosis

Maturitas

Volumn 65, Issue 4, 2010, Pages 299-300

  Rozenberg, Serge ^a  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; WNT PROTEIN; ZOLEDRONIC ACID;

BONE REMODELING; DRUG TARGETING; EDITORIAL; HUMAN; OSTEOLYSIS; OSTEOPOROSIS; SIGNAL TRANSDUCTION;

BONE DENSITY CONSERVATION AGENTS; HUMANS; OSTEOPOROSIS;

EID: 77649181717     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2010.01.011     Document Type: Editorial

References (13)

1. Gallagher, and Sai. Molecular biology of bone remodeling: implications for new therapeutic targets for osteoporosis. Maturitas 65 (2010) 301-307
2. Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
3. Boyle W.J., Simonet W.S., and Lacey D.L. Osteoclast differentiation and activation. Nature 423 May(6937) (2003) 337-342
4. Smith M.R., Egerdie B., Hernández Toriz N., et al. Denosumab HALT Prostate Cancer Study Group. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361 August(8) (2009) 745-755 [Epub 2009 August 11]
5. Cummings S.R., San Martin J., McClung M.R., et al. FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361 August(8) (2009) 756-765 [Epub 2009 August 11. Erratum in: N Engl J Med. 2009 November 5;361(19):1914]
6. Ellis G.K., Bone H.G., Chlebowski R., et al. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Res Treat 118 November(1) (2009) 81-87 [Epub 2009 March 24]
7. Fizazi K., Lipton A., Mariette X., et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 27 April(10) (2009) 1564-1571 [Epub 2009 February 23]
8. Brown J.P., Prince R.L., Deal C., et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24 January(1) (2009) 153-161
9. Bone H.G., Bolognese M.A., Yuen C.K., et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 93 June(6) (2008) 2149-2157 [Epub 2008 April 1]
10. McClung M.R., Lewiecki E.M., Cohen S.B., et al. AMG 162 Bone Loss Study Group. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354 February(8) (2006) 821-831
11. Anastasilakis A.D., Toulis K.A., Goulis D.G., et al. Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. Horm Metab Res 41 October(10) (2009) 721-729
12. Stoch S.A., Zajic S., Stone J., et al. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. Clin Pharmacol Ther 86 August(2) (2009) 175-182 [Epub 2009 May 6]
13. Stopeck A., Body J.J., Fujiwara Y., et al. Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study. Eur J Cancer 7 3 (2009) 2 [Abstract 2LBA]